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SUMMARY
Serology is an important tool for the diagnosis of alveolar echinococcosis (AE) in humans. In order to improve
serodiagnostic performance, we have developed an in vitro-produced Echinococcus mulilocularis metacestode vesicle
ﬂuid (EmVF) antigen for application in an immunoblot assay. Immunoblot analysis of EmVF revealed an abundant
immunoreactive band triplet of 20–22 kDa, achieving a sensitivity of 100% based on the testing of sera from 62
pre-operative and pre-treatment cases of active and inactive AE. Thus, the EmVF-immunoblotting allowed the speciﬁc
detection of cases seronegative by the Em2- and/or EmII/3–10-ELISA, usually attributable to abortive, inactive cases of
AE.The speciﬁcity of the EmVF-immunoblotting did not allow discrimination betweenAE and cystic echinococcosis (CE)
but was 100% with respect to non-Echinococcus parasitic infections or cancer malignancies. Based on the ﬁndings of this
study, it is recommended that the current ELISA test combination (Em2- and II/3–10-ELISA) be complemented with
EmVF-immunoblotting, allowing an improved diagnosis of both clinical and subclinical forms of AE, including those
associated with E. multilocularis-speciﬁc antibody reactivities not detectable by ELISA.
Key words: Echinococcus multilocularis, in vitro cultivation, immunoblotting, enzyme-linked immunosorbent assay
(ELISA).
INTRODUCTION
Human alveolar echinococcosis (AE) is caused by
the infection with the metacestode (larval stage) of
E. multilocularis (see Gottstein and Reichen, 2002;
Gottstein, 2004; Ito and Craig, 2003). Serological
tests based on the enzyme-linked immunosorbent
assay (ELISA) are useful for the early diagnosis of
AE (i.e. before the disease becomes clinically mani-
fest), at a time point when radical surgical resection
of the parasitized tissue ismore likely (Gottstein et al.
2001). Several years ago, the early immunodiagnosis
of AE was improved via the isolation and application
in ELISA of an aﬃnity-puriﬁed, native metacestode
Em2 antigen (Gottstein et al. 1983) and the re-
combinant antigen II/3–10 (Mu¨ller et al. 1989;
Felleisen and Gottstein, 1993) representing a highly
antigenic subfragment of E. multilocularis antigen
II/3 (Vogel et al. 1988). The combined application
of these antigens allowed discrimination between
AE and cystic echinococcosis (CE, caused by the
metacestode of E. granulosus) as well as cysticercosis
(caused by the metacestode of Taenia solium) and
other diseases caused by various parasitic nematodes
and trematodes. Other research groups have also
produced recombinant E. multilocularis antigens
(EM10, Frosch et al. 1991; Em4, Hemmings and
McManus, 1991; rEm18, Xiao et al. 2003) which
exhibited similar diagnostic operating characteristics
and all proved to represent the same ERM-gene
family (Brehm et al. 1999). Despite the excellent
diagnostic qualities of, for example, the ELISA
utilizing the antigens Em2 and II/3–10, either a lack
of reactivity or some cross-reactivity was observed in
a small number of conﬁrmed AE cases, thus ham-
pering interpretation in view of these peculiar cases
(Gottstein et al. 1993). Weak antibody reactivity is a
relatively common feature in AE cases, particularly
when related to certain clinical scenarios, such as a
recently acquired infection or an abortive course of
infection (i.e. degradation or death of the parasite in
tissues). Another issue is that cross-reactive serum
antibodies, frequently occurring in cancer patients
(e.g. Pﬁster et al. 1999; Poretti et al. 1999) may
complicate the interpretation of results.
Immunoblot analysis is an important approach
that suitably complements the ELISA-based im-
munodiagnosis of CE (Poretti et al. 1999; Liance
et al. 2000;Doiz et al. 2001; Furuya et al. 2004;Akisu
et al. 2005). An immunoblot for CE, previously
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developed in our laboratory based on the use of
E. granulosus hydatid cyst ﬂuid (EgHF) antigen,
relied on the detection of a genus-speciﬁc 8 kDa
subunit of antigen B and 2 other immunodiagnostic
antigens of 29 and 34 kDa (Poretti et al. 1999). In this
study, antigen B and, if detectable, the 29 kDa and
34 kDa antigens were shown to be genus-speciﬁc and
allowed the diagnosis of AE and CE, with a sensi-
tivity of 91% and a speciﬁcity of 97% (antigen B) or
94% (29 and 34 kDa antigens), respectively. Some
years ago, Ito et al. (1999) established 2 immunoblots
for the diagnosis of AE, which were based on the use
of fractions containing either semi-puriﬁed 8 kDa
E. granulosus antigen B or an 18 kDa antigen (Em18),
enriched by isoelectric focusing from an E. multi-
locularis protoscolex extract. A large-scale serological
evaluation of this ‘dual immunoblot system’ re-
vealed the genus-speciﬁc characteristics of antigen
B in that 92% of the CE sera and 79% of the AE sera
reacted with this antigen. Conversely, the Em18
antigen was shown to detect AE with a diagnostic
sensitivity of 97% and a moderate speciﬁcity of
74%, and had potential to diﬀerentiate AE from
CE. Liance et al. (2000) evaluated a commercial
immunoblot (Echinococcus Western Blot IgGTM,
LDBIO Diagnostics, Lyon, France) that employs a
whole larval antigen from E. multilocularis. In this
test system, the serological reactivity with a 7 kDa
band and/or a diﬀuse 26 to 28 kDa band was
indicative of the presence of Echinococcus-speciﬁc
antibodies. The diagnostic sensitivities of the
immunoblot were determined to be 96.7% for AE
and 98% for CE, respectively. Cross-reactivity was
shown using sera from patients with neurocysti-
cercosis (7 of 20) or Schistosoma mansoni infection
(3 of 18 sera). In a more recent study, Korkmaz et al.
(2004) tested 2 E. multilocularis metacestode anti-
gens, Em70 and Em90, and achieved a sensitivity of
100% and a speciﬁcity of 99.1% for the diagnosis of
AE. Most of these studies did or could not include
(due to unavailability) ‘diagnostically critical’ sera,
such as those derived from patients with abortive AE
or with very low levels of anti-E. multilocularis serum
antibodies due to degenerative or dead metacestodes.
Such sera frequently remain negative when tested
against native or recombinant E. multilocularis anti-
gens. Therefore, any improvement of the sensitivity
and speciﬁcity of an antigen or a test for the sero-
diagnosis of AE is considered a signiﬁcant advance.
In the present study, we developed an improved
immunoblot assay for the speciﬁc diagnosis of AE,
irrespective of the form of disease. This assay utilizes
an in vitro-produced E. multilocularis vesicle ﬂuid
(EmVF) antigen, as an alternative to native anti-
gens usually obtained from alveolar cysts from
experimentally infected rodents. Together with the
present Em2- and II/3–10-ELISA (Gottstein et al.
1993), this immunoblot method allows the accurate
diagnosis of both clinical and subclinical cases of AE.
MATERIALS AND METHODS
Preparation of E. multilocularis vesicle ﬂuid
(EmFV ) antigen
The EmVF antigen was obtained by aseptic aspir-
ation of ﬂuid from fertile vesicular cysts, axenically
cultivated in vitro as described previously (Hemphill
and Gottstein, 1995). EmVF was complemented
with 1 mmol of the proteinase inhibitor phenyl-
methyl-sulfonyl ﬂuoride (PMSF), centrifuged at
14 000 g for 10 min and the supernatant sub-
sequently stored frozen atx80 xC until use. In order
to validate individual batches of ﬂuid, the protein/
carbohydrate ratio was required to range between
4 : 1 and 5 : 1, the protein concentration between 0.7
and 0.9 mg/ml (EmVF with higher protein con-
centrations were discarded). Also, the immunoblot
characteristics of the EmVF had to be consistent with
those described herein.
Human sera
Well-deﬁned sera from 62 Central European AE
patients (54 of them with active hepatic lesions, and
8 of them had fully calciﬁed lesions and thus rep-
resented inactive or ‘abortive’ cases) were used for
assessing the primary diagnostic sensitivity of the
tests for AE. Inactivity of metacestodes was proven
either by post-diagnostic surgical removal of parasite
material, with a subsequent viability assessment as
described by Rausch et al. (1987) or by extensive
clinical and subsequent computer tomography or
X-ray imaging of the patients (see Gottstein et al.
2001). Therefore, all sera were sampled prior to any
therapeutic or surgical intervention. Each diagnosis
of AE had been conﬁrmed by clinical, histological
(if feasible) and serological means.
Sera used for assessing test speciﬁcities were
obtained from patients with clinically, parasit-
ologically and/or histologically proven infections,
involving the following parasites (disease and num-
ber of sera obtained from patients are in parenth-
eses) : E. granulosus (cystic echinococcosis, 22 sera),
Fasciola hepatica (fascioliasis, 7 sera), Schistosoma
spp. (schistosomiasis, 7 sera), Taenia solium (cysti-
cercosis, 10 sera), Ascaris lumbricoides (ascariasis,
7 sera), Strongyloides stercoralis (strongyloidiasis,
6 sera), Toxocara canis (toxocariasis ; visceral larva
migrans, 7 sera), Trichinella spiralis (trichinellosis,
7 sera) ; Onchocerca volvulus (ﬁlariasis, 6 sera),
and Entamoeba histolytica (amoebiasis, 7 sera). All
of these sera had been pre-selected based on their
‘positivity’ using homologous parasite antigens in
tests carried out routinely in our diagnostic labora-
tory in the University of Berne. Sera from 18 cancer
patients were also selected from a previous study
(Pﬁster et al. 1999) based on their serological re-
activity in Echinococcus tests, as described by Poretti
et al. (1999).
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Enzyme-linked immunosorbent assays (ELISAs)
These assays were carried out essentially as described
by Gottstein et al. (1993), by testing sera at a 1 : 100
dilution and using the following antigens (at
optimized coating concentrations) : EmVF-antigen
(2.8 mg protein per ml) ; EgHF antigen (5 mg protein
per ml) ; Em2 antigen (2.8 mg carbohydrates per
ml) ; II/3–10 antigen (1 mg protein per ml). All
Echinococcus-antigen-ELISAs employed in the
present study were ﬁrst calibrated to determine the
threshold for the discrimination between positive
and negative results. The actual cut-oﬀ value was
thus determined by testing blood donor sera, and
the threshold was set at a mean of the respective
OD405 nm values plus 3 standard deviations (cf.
Gottstein et al. 2001). When plotted, the respective
OD405 nm values essentially represented a normal
distribution. The blood donor sera were from
healthy Swiss persons and were selected based on an
even male-female ratio and an age range of between
20 and 65 years. By using the present selection
criteria, the negative control groups thus matched
the corresponding parameters of the 62 sera from the
Central European AE-patients. Inter-test and intra-
test variations were assessed by determining the
coeﬃcients of variation for reference negative and
positive sera, all having been tested in triplicate on
each test plate; variation of f15% was recorded,
which is considered acceptable for immunological
assays (Pﬁster et al. 1999). Since this latter ﬁnding
was essentially the same as described previously
(Gottstein et al. 1993), no modiﬁcation was required
for the present study.
Immunoblotting
Immunoblotting was performed as described pre-
viously for E. granulosus hydatid ﬂuid (EgHF)
antigen (Poretti et al. 1999), with the exception that
EmVF (7 mg per cm slot) was used instead of EgHF.
Sera were used at a dilution of 1 : 100.
Aﬃnity puriﬁcation of speciﬁc antibodies against the
20–22 and 8 kDa antigens
The aﬃnity puriﬁcation of speciﬁc antibodies against
the 2 immunodominant bands in the EmVF antigen
was performed essentially as described by Mu¨ller
et al. (1992). Brieﬂy, the region corresponding to
the 20–22 and 8 kDa antigens was excised from
the nitrocellulose, following sodium dodecyl-sulfate
polyacrylamide gel electrophresis (SDS-PAGE)
and blotting of the EmVF antigen. After washing
and blocking with phosphate-buﬀered saline (PBS,
pH 7.2) containing 0.3% Tween 20 (Sigma) for 1 h
at room temperature (22–24 xC), a strongly positive
serum from an AE patient, applied at a dilution
of 1 : 20 in PBS containing 0.3% Tween 20, was
incubated overnight at 4 xC. After washing the strips
in PBS containing 0.3% Tween 20 (3 times for
10 min each), the bound antibodies were eluted in
900 ml of low-pH buﬀer (50 mMTris, 50 mM glycine,
0.05% Tween 20, pH 2.6) for 5 min on ice, with
occasional vortexing. Subsequently, the strips were
removed, and 100 ml of 1 M Tris base was immedi-
ately added to neutralize the pH. The eluted
antibody fractions were centrifuged (10 000 g for
20 min) to remove any small nitrocellulose particles,
and bovine serum albumin (BSA) was added to a
ﬁnal concentration of 0.1%. The aﬃnity-puriﬁed
antibodies were stored at x20 xC and used for
immunoblotting at a dilution of 1 : 10.
Determination of protein
and carbohydrate concentrations
Soluble protein concentrations were determined
using a commercial assay (Bradford Kit, Bio-Rad,
Switzerland), employing bovine plasma gamma-
globulin as a standard. Carbohydrate concentrations
were estimated using the orcinol-sulfuric acid assay,
employing Dextran T-2000 as a standard (Miguez
et al. 1996).
RESULTS
Comparative serological analyses of various
Echinococcus antigen-ELISAs
The sensitivities for the ELISAs using diﬀerent
antigens for the serological diagnosis of AE or CE are
given in Table 1. The testing of ‘crude’ Echinococcus
Table 1. Diagnostic sensitivities of crude, puriﬁed,
and recombinant Echinococcus antigens for
immunodiagnosis of alveolar (AE) and cystic (CE)
echinococcosis by ELISA and immunoblot in
patients with conﬁrmed AE or CE
Assay
Sensitivity (%)*
AE active
(n=62)
AE calciﬁed
(n=8)
CE
(n=22)
ELISA:
EmVF 89 (55) 1/8 95 (21)
EgHF 81 (50) 0/8 91 (20)
Em2 90 (56) 6/8 n.d.#
II/3–10 79 (49) 0/8 n.d.#
EmVF+EgHF 89 (55) 1/8 95 (21)
Em2+II/3–10 97 (60) 6/8 n.d.#
All antigens 97 (60) 6/8 n.d.#
Immunoblot :
EmVF 100 (62) 8/8 50 (11)
* The number of positive samples is given in parenthesis ;
individual test results, see Fig. 1.
# Not done (n.d.), diagnostically irrelevant.
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Fig. 1. EmVF-immunoblot with sera from 62 patients with active alveolar echinococcosis (AE) (54 sera) ; degenerate
alveolar echinococcosis (non-viable metacestode) (AE, deg; 8 sera in total : 3 tested in analysis 1 [A1, 2nd blot strip
panel] and 5 in analysis 2 [A2, 4th blot strip panel]) ; cystic echinococcosis (CE, 22 sera) ; amoebiasis (7 sera) ;
cysticercosis (10 sera) ; ascariasis (7 sera); ﬁlariasis (6 sera) ; strongyloidiasis (7 sera); toxocariasis (7 sera); trichinellosis
(7 sera), fascioliasis (7 sera) ; and schistosomiasis (7 sera), and sera from cancer patients (18 sera). Molecular weight
markers (M) (left) are given in kilodaltons (kDa) and positions of the major immunoreactive bands (right) representing
65 kDa, 20–22 kDa, and 8 kDa antigens are indicated by arrows. As controls, blot strips incubated exclusively with
anti-human immunoglobulin-peroxidase conjugate (CON), or with negative (NEG) or postive (POS) serum were
included.
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Fig. 1 (Cont.). EmVF-, EgHF, Em2-, and II/3–10-ELISA values of the individual sera are listed on top of each strip.
For sera from cancer patients, borderline-negative ELISA results are indicated with asteriscs. Identiﬁcation of the
major antigens (Ag-identiﬁcation) and assessment of serological cross-reactivities among the corresponding bands
on the blot was performed by demonstrating the immunoreactivity with a polyclonal rabbit anti-II/3–10 antibody
(Rab a II/3) and antibodies aﬃnity-puriﬁed on bands representing the 22–20 kDa (Hu a 20–22), and 8 kDa (Hu a 8)
antigens. a Not done (n.d.), as pre-selected based on EgHF-positivity according to Pﬁster et al. (1999).
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metacestode antigens using well-deﬁned sera from
untreated AE patients revealed that the EmVF-
ELISA had a better diagnostic sensitivity than
the EgHF-ELISA (89% vs 81%); most of the sera
yielded positive results in the 2 ELISAs and also
exhibited similar values. Furthermore, all sera
positive in the EgHF-ELISA were also positive in
the EmVF-ELISA. However, the accumulation of
results achieved from both assays did not improve
the diagnostic sensitivity. The individual diagnostic
sensitivities of the Em2-ELISA and the II/3–10-
ELISA were 90% and 79%, respectively. Interest-
ingly, the Em2-ELISA scored positive for 6 of 8 sera
from inactive AE cases with necrotic lesions (see
Fig. 1). The cumulative diagnostic sensitivity from
the Em2- and II/3–10-ELISAs (as achieved in the
Em2plus-ELISA reported earlier, seeGottstein et al.
1993) was high, and allowed detection of 97% of AE
cases included in the present study (Table 1). Hence,
no further improvement in diagnostic sensitivity
was achieved when the results from all 4 ELISAs
assessed were accumulated.
Upon diagnosis, patients with CE demonstrated
EmVF-ELISA reactivity, in that 21 of 22 sera scored
positive values. Conversely, 20 sera from this panel
were positive in the EgHF-ELISA (see Table 1).
Accordingly, the EmVF-ELISA exhibited a better
diagnostic sensitivity than the EgHF-ELISA (95%
vs. 91%). Furthermore, most of sera positive in the 2
ELISAs showed similar values, and the accumulation
of the results from both tests did not improve the
diagnostic sensitivity (Table 1). As expected, the
antigens Em2 and II/3–10 previously proven to be
suitable for the speciﬁc serodiagnosis of AE did not
react with the majority of sera from CE patients (see
Fig. 1).
Diagnostic speciﬁcities linked to the diﬀerent
ELISAs and to potentially cross-reactive sera from
patients with other parasitoses are listed in Table 2.
Sera from patients with Taenia solium cysticercosis
(n=10) showed low to moderate cross-reactivity
in the EmVF-, Em2- and II/3–10-ELISAs (f2
cross-reactive sera) but high cross-reactivity in
the EgHF-ELISA (6 cross-reactive sera). Also, some
cross-reactivity was observed for sera from patients
with nematode (n=33; 17, 20, 0 and 2 cross-reactive
sera in the EmVF-, EgHF-, Em2-, and II/3–10-
ELISAs, respectively) and trematode infections
(n=14; 0, 1, 2 and 1 cross-reactive serum/sera in
the EmVF-, EgHF-, Em2- and II/3–10-ELISAs,
respectively). Sera from patients with hepatic
amoebiasis were also assessed for possible cross-
reactivity, because diagnostic images (by computer
tomography or X-ray) of liver lesions due to this
disease can be confused with those caused by AE.
In this case, cross-reactivity was restricted to 1 serum
sample, which was weakly positive in the Em2-
ELISA. In summary, the overall speciﬁcities of
the diﬀerent ELISAs related to non-Echinococcus
parasitic infections were determined to be 72%
(EmVF-ELISA), 58% (EgHF-ELISA), 95% (Em2-
ELISA) and 92% (II/3–10-ELISA).
Since the EgHF-ELISA used previously for
the screening of CE was associated with relatively
frequent false-positive reactions in cancer patients
(Pﬁster et al. 1999; Poretti et al. 1999), 18 such
cross-reactive sera were speciﬁcally selected and
tested in the diﬀerent E. multilocularis-ELISAs. In
the EmVF-ELISA, 8 of these sera scored positive
and another 3 exhibited marginal reactivity (ELISA-
value:fx2 antibody units, AU). Conversely, in the
Em2-ELSA, all samples from the panel of cross-
reactive sera were test negative, but 9 of them showed
marginal reactivity (fx2 AU). Within this panel,
2 sera were test positive in the II/3–10-ELISA,
whereas 14 other sera gave low values (fx2 AU).
Table 2. Diagnostic speciﬁcities of crude, puriﬁed, and recombinant Echinococcus antigens in view of
potential cross-reactions with serum antibodies from patients with various parasite infections or
cancer malignancies
Assay
Number of positive samples*
Relative overall speciﬁcity (%)·
related to non-Echinococcus
parasitic infections (n=64)
Amoebiasis
(n=7)
Cysticercosis
(n=10)
Nematodes**
(n=33)
Trematodes#
(n=14)
Cancer
(n=18)
ELISA:
EmVF 0 1 17 0 8 72 (18)
EgHF 0 6 20 1 n.d.b 58 (27)
Em2 1 0 0 2 0 95 (3)
II/3–10 0 2 2 1 2 92 (5)
Immunoblot :
EmVF 0 0 0 0 0 100 (0)
* Individual test results, see Fig. 1.
** Diseases (n) : ascariasis (7), ﬁlariasis (6), strongyloidiasis (6), toxocariasis (7), trichinellosis (7).
# Diseases (n) : fascioliasis (7), schistosomiasis (7).
· The number of positive samples is given in parenthesis.
b Not done (n.d.), as preselected upon EgHF-positivity according to Pﬁster et al. (1999).
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Serological evaluation of the EmVF-immunoblot
EmVF-immunoblot analysis using sera from AE
patients revealed major immunoreactive bands of
y65, 20–22 (triplet), and 8 (doublet) kDa (Fig. 1).
While the molecules representing the 20–22 triplet
and the 8 kDa doublet require biochemical charac-
terization (see Discussion section), the 65 kDa band
represents a full-length antigen II/3 (Felleisen and
Gottstein, 1993), supported by demonstrating the
reactivity of this band employing a hyperimmune
serum raised against antigen recII/3–10, a recom-
binant subfragment of E. multilocularis antigen II/3
(see Vogel et al. 1988; Mu¨ller et al. 1989). A pre-
liminary evaluation of the blotting method in our
diagnostic laboratory (data not shown) had indicated
that neither the 65 kDa antigen II/3 nor the 8 kDa
antigen achieved optimum diagnostic sensitivity
or speciﬁcity. Therefore, all immunoblot strips
obtained in the present study were scored with the
criterion of positivity being a detectable signal for the
20–22 kDa triplet.
Immunoblot data and the corresponding ELISA-
results of individual sera are shown in Fig. 1. The
performance of immunoblotting with regard to sen-
sitivity and speciﬁcity is summarized in Tables 1 and
2, respectively. When 62 sera from AE patients were
tested in terms of their reactivity with the 20–22 kDa
band triplet, the immunoblot revealed a diagnostic
sensitivity of 100%. In particular, the immunoblot
also detected all 8 inactive AE cases with degenerate
liver lesions (Fig. 1). Here, respective testing con-
sisted of 2 separate analyses (see Fig. 1; analysis 1
[panel of strips indicated as A1] and 2 [panel of strips
indicated as A2]) that were performed with 2 diﬀer-
ent batches of EmVF antigen. As displayed in Fig. 1,
in the second immunoblot analysis (A2), a few
diagnostically irrelevant bands (e.g. a 10 kDa and
35 kDa bands) were more pronounced as compared
with the ﬁrst analysis (A1). Furthermore, the
20–22 kDa band triplet was not adequately resolved
in the blot strips from analysis A2. However, despite
this inconsistency, sera from all 8 inactive cases
exhibited an appropriate proﬁle for the 20–22 kDa
band triplet.
The relatively high rate of cross-reactivity (50%)
determined for sera from patients with CE (Table 1)
demonstrated that the immunoblot was not suitable
for a serological diﬀerentiation between AE and CE.
However, the speciﬁcity of the immunoblot, con-
sidering sera from patients with parasitic infections
other than Echinococcus, was 100% (Table 2). In this
case, the scoring of strips incubated with sera from
patients with T. solium cysticercosis was somewhat
aﬀected by the occasional detection of 2 faint bands
above the diagnostically relevant 20–22 kDa triplet.
However, strictly considering the diagnostic criteria
(i.e. the position and nature of the immuno-reactivity
of bands), such sera were scored as negative.
None of the 18 sera from cancer patients tested
had non-speciﬁc reactivity with the diagnostic
20–22 kDa triplet. However, some of them reacted
weakly with the 65 kDa band (9 positive sera) and the
8 kDa doublet (1 positive serum).
A possible antigenic relationship between the
65 kDa antigen II/3, the 20–22 kDa and the 8 kDa
antigens was tested by incubating EmVF-blot strips
with polyclonal antibodies speciﬁc to E. multi-
locularis antigen II/3- and aﬃnity-puriﬁed poly-
clonal antibodies directed against the 20–22 or 8 kDa
antigen. In this immunoblot (see Fig. 1, last panel),
each of the 3 monospeciﬁc antibody fractions reacted
individually with the corresponding antigen but did
not exhibit detectable cross-reactivity with any of the
other antigens on the blot. This result indicated that
the 65, 20–22 and 8 kDa antigens are distinct and do
not represent diﬀerent breakdown products and/or
conformational variants or isoforms of the same
molecule.
DISCUSSION
Substantial eﬀorts have been undertaken to
maximize, or at least optimize, the perfomance of
serological tests for the diagnosis of echinococcosis,
and many studies have yielded novel test systems or
antigens to enhance both diagnostic sensitivity and
speciﬁcity (Gottstein et al. 1993; Poretti et al. 1999;
Liance et al. 2000; Sako et al. 2002; Ito and Craig,
2003; Xiao et al. 2003; Kormaz et al. 2004; Mamuti
et al. 2004). New epidemiological and clinical
ﬁndings have shown unusual presentations of infec-
tions that also exhibit unusual serological proﬁles
upon diagnosis. For example, hepatic lesions con-
taining degrading or dead E. multilocularis cysts
may stimulate weak anti-Em2-antibody responses,
whereas anti-II/3–10 (and thus also anti-EM10, Em4
and/or Em18) responses are not detectable in such
patients (Gottstein et al. 1996; Zingg et al. 2004;
Matsumoto et al. 2006). Also, the technique of
immunoblotting has gained increased attention for
the diagnosis of echinococcosis (Ito et al. 1999;
Poretti et al. 1999; Kormaz et al. 2004). Crude or
semi-puriﬁed antigens produced from the meta-
cestode stage obtained from experimentally infected
rodents have been used for these immunoblots. Two
problems can be associated with this approach.
One relates to the presence of host proteins in such
extracts, which may relate to non-speciﬁc antibody
reactivity to host epitopes or which may sterically
cover and thus hide parasite epitopes otherwise
accessible to antibodies.
In the present study, a signiﬁcant improvement
was achieved in that a highly sensitive (in relation
to AE) and speciﬁc (regarding diseases other than
AE and CE) immunoblot using axenically in vitro-
produced vesicle ﬂuid from E. multilocularis meta-
cestodes as an antigen was developed. Although the
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corresponding E. granulosus hydatid ﬂuid antigen
can be readily obtained from fertile hydatid cysts, it
has been shown to contain substantial amounts of
host proteins that can lead to false-positive (anti-
host-protein) reactions (Gottstein et al. 1987). The in
vitro culture of E. multilocularis metacestodes has
been established as a valuable and commonly used
alternative to animal experimentation, as reﬂected by
numerous publications in the ﬁeld (e.g. reviewed by
Hemphill et al. 2002; Brehm et al. 2006). Preliminary
experience with the EmVF antigen produced using
the same procedure has already been gained pre-
viously by ELISA (Romig et al. 1999) and within
the context of cell-immunological investigations of
cytokines in both AE patients (Sturm et al. 1995) and
mice experimentally infected with E. multilocularis
metacestode vesicles (Dai et al. 2001).
The present culture system serves as a continuous
source for an almost unlimited supply of EmVF
antigen from a well-deﬁned line of E. multilocularis,
which is devoid of potentially interfering host
components. This oﬀers an excellent basis for the
standardization of serological tests, as we have shown
that antigenic variation can be expressed among
diﬀerent isolates of E. multilocularis from naturally
infected rodents (Gottstein, 1991). Compared with
the other Echinococcus immunoblots established thus
far (Ito et al. 1999; Poretti et al. 1999; Liance et al.
2000; Kormaz et al. 2004), the EmVF-blot exhibits
a relatively simple immunoreactive banding proﬁle,
dominated by the diagnostic 20–22 kDa triplet.
Although not yet proven experimentally, the simi-
larity in antigenic abundance among the bands
within the triplet suggests that the 20–22 kDa
antigen represents a protein with diﬀerential con-
formations, post-translational modiﬁcation (such
as glycosylation) and/or degradation forms rather
than a set of diﬀerent proteins of similar sizes.
Consistent with diﬀerential glycosylation is the
ﬁnding that individual bands within this pattern are
smeary.
In the present study, we tested the hypothesis that
the protein(s) represented in the 20–22 kDa triple
band correspond to the E. multilocularis protoscolex
antigen Em18, identiﬁed previously (Sako et al.
2002) as an 18 kDa major proteolytic degradation
product of the 65 kDa antigen II/3. However,
speciﬁc antibodies puriﬁed to antigen II/3 bound to
intact antigen II/3 (appearing on the EmVF-blot as a
65 kDa band) did not react with the 20–22 kDa
triplet, refuting this hypothesis. Hence, the 20–22
kDa triplet does not appear to contain any antigen
II/3 components. Interestingly, the 18 kDa band did
not represent components of the EmVF-antigen.
This may either be due to 1 or more biological
characteristics ofE. multilocularis, in that this band is
detected in crude extracts of protoscoleces and/or
when PMSF is added as a protease inhibitor to pre-
vent proteolytic degradation (following the isolation
of the ﬂuid). Also, by demonstrating a lack of anti-
body cross-reactivity between the 20–22 kDa and the
8 kDa antigen (a subunit of antigen B) in the same
immunoblot analysis, any immunological relation-
ship between these 2 abundant antigens was not
supported.
The present and previous investigations (Mu¨ller
et al. 1989; Gottstein et al. 1993) have shown that
recombinant antigen II/3–10 is an excellent diag-
nostic reagent, allowing a sensitive and speciﬁc
diagnosis of AE by ELISA, conﬁrmed by other
researchers (Frosch et al. 1991; Hemmings and
McManus, 1991; Xiao et al. 2003). Using immuno-
reactivity to the native 65 kDa antigen II/3 as a
diagnostic criterion, we showed herein that the
majority of AE and some CE sera tested positive, but
also sera from patients with some other disorders
did not completely lack reactivity. Such apparent
cross-reactivity was also observed with the 8 kDa
band known as the 8 kDa subunit of E. multilocularis
antigen B (cf. Mamuti et al. 2004). Since cross-
reactivity complicates the scoring of the EmVF-
immunoblot and the interpretation of the results,
only the abundant 20–22 kDa bands were considered
as diagnostic markers. This approach allowed the
diagnosis of 100% of AE cases and also the serological
detection of all cases with an inactiveE. multilocularis
infection. The immunoblot analysis did not con-
sistently discriminate between AE and CE but ex-
hibited a maximal speciﬁcity compared with other
parasitoses. This ﬁnding was supported by results
obtained by testing sera from patients suﬀering from
various cancers. In a previous evaluation focused
on the diagnostic speciﬁcity of the EgHF-ELISA
(Poretti et al. 1999), a substantial number (6.3%) of
these sera tested false-positive, and this result was
considered to complicate the serological diagnosis
of echinococcosis. In the present study, only the
EmVF- and II/3–10-ELISAs occasionally produced
similar false-positive results, but this was not the case
for the EmVF-immunoblot.
Taken together, the present study revealed that
the EmVF-immunoblot ideally complements the
Em2- and II/3–10-ELISAs for the serological diag-
nosis of AE. In combination with these 2 ELISAs,
a reliable serodiagnosis of both active and inactive
E. multilocularis infections in humans could be
achieved. Prospectively, we plan to identify the
nature of these 20–22 kDa proteins, to address their
role in the host-parasite interplay and, if appropriate,
to clone respective gene(s).We also plan to determine
the value of the EmVF-immunoblot to monitor AE
patients serologically after surgery and during long-
term benzimidazole chemotherapy.
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